106 Immune Mediated Adverse Events and Outcomes in Malignant Mesothelioma Treated with Nivolumab plus Ipilimumab

Lung Cancer 2026

View at publisher
Authors: Anna McCallum
DOI: 10.1016/j.lungcan.2026.109055
Cited by: 0
References: 1

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Occupational and environmental lung diseases Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Lung Cancer
Volume
212
Pages
109055–109055
Publication date
1 February 2026
Language
EN